Intrapancreatic transplantation of cell progeny after expansion of ALDHhi cells with or without BMS493 shows no reduction of hyperglycemia in Streptozotocin-treated NOD/SCID mice. Thus, Umbilical cord blood (UCB)-derived ALDHhi cells effectively lost islet regenerative capacity during ex vivo expansion[1].
In Vitro
BMS493 (100 nM; 6 days; ALDHhi UCB cells) treatment shows a twofold increase in the number of ALDHhi cells available for transplantation compared with untreated controls. Newly expanded ALDHhi cells shows increased numbers of CD34 and CD133-positive cells, as well as a reduction in CD38 expression, a marker of hematopoietic cell differentiation[1]. Cell Viability Assay[1] Cell Line: ALDHhi UCB cells Concentration: 100 nM Incubation Time: 6 days Result: Showed a twofold increase in the number of ALDHhi cells available for transplantation compared with untreated controls.
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Elgamal RM, et al. BMS 493 Modulates Retinoic Acid-Induced Differentiation During Expansion of Human Hematopoietic Progenitor Cells for Islet Regeneration. Stem Cells Dev. 2018 Aug 1;27(15):1062-1075.
[2]. Yu Z, et al. Apoptosis induced by atRA in MEPM cells is mediated through activation of caspase and RAR. Toxicol Sci. 2006 Feb;89(2):504-9.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.